Intravenous morphine for management of cancer pain (Q37740515)

22 August 2017

1 reference

title

Intravenous morphine for management of cancer pain (English)

1 reference

22 August 2017

0 references

1 reference

Sebastiano Mercadante

series ordinal

object named as

Sebastiano Mercadante

1 reference

22 August 2017

publication date

1 May 2010

1 reference

Lancet Oncology Commission

22 August 2017

published in

1 reference

22 August 2017

1 reference

22 August 2017

1 reference

22 August 2017

page(s)

484-489

1 reference

Morphine and alternative opioids in cancer pain: the EAPC recommendations

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970350-X

7 January 2021

The efficacy and side effects of continuous infusion intravenous morphine (CIVM) for pain and symptoms due to advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970350-X

7 January 2021

Parenteral morphine prescribing patterns among inpatients with pain from advanced cancer: a prospective survey of intravenous and subcutaneous use.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970350-X

7 January 2021

Rapid titration with intravenous morphine for severe cancer pain and immediate oral conversion

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970350-X

7 January 2021

Clinical and financial analysis of an acute palliative care unit in an oncological department.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970350-X

7 January 2021

Breakthrough pain: definition, prevalence and characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970350-X

7 January 2021

The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970350-X

7 January 2021

Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970350-X

7 January 2021

A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970350-X

7 January 2021

Breakthrough pain: on the road again

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970350-X

7 January 2021

A titration strategy is needed to manage breakthrough cancer pain effectively: observations from data pooled from three clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970350-X

7 January 2021

Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970350-X

7 January 2021

Intravenous morphine for breakthrough (episodic-) pain in an acute palliative care unit: a confirmatory study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970350-X

7 January 2021

Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970350-X

7 January 2021

Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970350-X

7 January 2021

Nasal administration of opioids for pain management in adults

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970350-X

7 January 2021

The analgesic efficacy and safety of a novel intranasal morphine formulation (morphine plus chitosan), immediate release oral morphine, intravenous morphine, and placebo in a postsurgical dental pain model

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970350-X

7 January 2021

Opioid dose titration for severe cancer pain: a systematic evidence-based review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970350-X

7 January 2021

Acute pain in advanced cancer: an opioid dosing strategy and illustration

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970350-X

7 January 2021

Intravenous morphine for rapid control of severe cancer pain

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970350-X

7 January 2021

Intravenous titration with morphine for severe cancer pain: report of 28 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970350-X

7 January 2021

A prospective study evaluating the response of patients with unrelieved cancer pain to parenteral opioids

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970350-X

7 January 2021

Optimization of opioid therapy for preventing incident pain associated with bone metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970350-X

7 January 2021

Intravenous versus subcutaneous morphine titration in patients with persisting exacerbation of cancer pain

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970350-X

7 January 2021

Cancer pain emergencies: A protocol for management

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970350-X

7 January 2021

Intravenous morphine for emergency treatment of cancer pain

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970350-X

7 January 2021

Opioid titration in cancer pain: a critical review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970350-X

7 January 2021

A prospective, within-patient, crossover study of continuous intravenous and subcutaneous morphine for chronic cancer pain

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970350-X

7 January 2021

Responders and non-responders to post-operative pain treatment: the loading dose predicts analgesic needs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970350-X

7 January 2021

A randomized double-blind crossover comparison of continuous and intermittent subcutaneous administration of opioid for cancer pain

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970350-X

7 January 2021

Use of the subcutaneous route for the administration of narcotics in patients with cancer pain

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970350-X

7 January 2021

Oral morphine and respiratory function amongst hospice inpatients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970350-X

7 January 2021

Is there a higher risk of respiratory depression in opioid-naïve palliative care patients during symptomatic therapy of dyspnea with strong opioids?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970350-X

7 January 2021

Respiratory function during parenteral opioid titration for cancer pain

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970350-X

7 January 2021

Experimental pain stimulates respiration and attenuates morphine-induced respiratory depression: a controlled study in human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970350-X

7 January 2021

Insufficient effectiveness of 5-hydroxytryptamine-3 receptor antagonists due to oral morphine administration in patients with cisplatin-induced emesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970350-X

7 January 2021

10.1016/S1470-2045(09)70350-X

Identifiers

DOI

1 reference

22 August 2017

1 reference